Pharmacological inhibition of EGFR has been shown to reduce high-fat (HF) diet-induced liver injury in mouse models of NAFLD [17,18], suggesting that targeting EGFR signaling may hold promise as a potential therapeutic approach for NASH. This evidence concerns the gene EGFR and metabolic dysfunction-associated steatohepatitis.